JP2021515017A5 - - Google Patents
Info
- Publication number
- JP2021515017A5 JP2021515017A5 JP2020546443A JP2020546443A JP2021515017A5 JP 2021515017 A5 JP2021515017 A5 JP 2021515017A5 JP 2020546443 A JP2020546443 A JP 2020546443A JP 2020546443 A JP2020546443 A JP 2020546443A JP 2021515017 A5 JP2021515017 A5 JP 2021515017A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- optionally
- subject
- antibody
- months
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024002970A JP2024045219A (ja) | 2018-03-07 | 2024-01-12 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639891P | 2018-03-07 | 2018-03-07 | |
| US62/639,891 | 2018-03-07 | ||
| US201862736343P | 2018-09-25 | 2018-09-25 | |
| US62/736,343 | 2018-09-25 | ||
| PCT/US2019/021024 WO2019173523A1 (en) | 2018-03-07 | 2019-03-06 | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002970A Division JP2024045219A (ja) | 2018-03-07 | 2024-01-12 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021515017A JP2021515017A (ja) | 2021-06-17 |
| JPWO2019173523A5 JPWO2019173523A5 (https=) | 2022-03-14 |
| JP2021515017A5 true JP2021515017A5 (https=) | 2022-03-14 |
| JP7471227B2 JP7471227B2 (ja) | 2024-04-19 |
Family
ID=67845742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546443A Active JP7471227B2 (ja) | 2018-03-07 | 2019-03-06 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
| JP2024002970A Pending JP2024045219A (ja) | 2018-03-07 | 2024-01-12 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002970A Pending JP2024045219A (ja) | 2018-03-07 | 2024-01-12 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210030888A1 (https=) |
| EP (1) | EP3762032A4 (https=) |
| JP (2) | JP7471227B2 (https=) |
| KR (1) | KR20200130356A (https=) |
| CN (1) | CN112105388A (https=) |
| AU (1) | AU2019231696B2 (https=) |
| BR (1) | BR112020018092A2 (https=) |
| CA (1) | CA3091217A1 (https=) |
| IL (1) | IL276768A (https=) |
| MX (1) | MX2020008613A (https=) |
| SG (1) | SG11202007865VA (https=) |
| UA (1) | UA129351C2 (https=) |
| WO (1) | WO2019173523A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| WO2019217455A1 (en) | 2018-05-07 | 2019-11-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| WO2022111618A1 (zh) * | 2020-11-26 | 2022-06-02 | 正大天晴药业集团股份有限公司 | 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物 |
| AU2022238571A1 (en) | 2021-03-18 | 2023-09-14 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| CN114569734B (zh) * | 2022-01-17 | 2023-08-29 | 北京化工大学 | 一种基于还原敏感聚合物递送阳离子铂药的纳米粒的制备方法 |
| WO2023213960A1 (en) * | 2022-05-06 | 2023-11-09 | Genmab A/S | Methods of treating cancer with anti-tissue factor antibody-drug conjugates |
| WO2024067864A1 (en) * | 2022-09-30 | 2024-04-04 | Shanghai Junshi Biosciences Co., Ltd. | Anti-lair1 antibodies and their uses |
| KR20250057675A (ko) * | 2023-10-19 | 2025-04-29 | (주)셀트리온 | 캄프토테신 유도체를 포함하는 항-Tissue factor 항체-약물 접합체 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA109633C2 (uk) * | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| JP6055404B2 (ja) * | 2010-06-15 | 2016-12-27 | ゲンマブ エー／エス | 組織因子に対するヒト抗体薬物結合体 |
| HUE055109T2 (hu) * | 2015-09-11 | 2021-11-29 | Genmab As | Adagolási rendek TF elleni antitest és gyógyszer konjugátumaihoz |
-
2019
- 2019-03-06 CN CN201980031334.6A patent/CN112105388A/zh active Pending
- 2019-03-06 BR BR112020018092-0A patent/BR112020018092A2/pt unknown
- 2019-03-06 UA UAA202005163A patent/UA129351C2/uk unknown
- 2019-03-06 CA CA3091217A patent/CA3091217A1/en active Pending
- 2019-03-06 EP EP19764722.5A patent/EP3762032A4/en active Pending
- 2019-03-06 JP JP2020546443A patent/JP7471227B2/ja active Active
- 2019-03-06 US US16/978,539 patent/US20210030888A1/en active Pending
- 2019-03-06 MX MX2020008613A patent/MX2020008613A/es unknown
- 2019-03-06 AU AU2019231696A patent/AU2019231696B2/en active Active
- 2019-03-06 KR KR1020207028401A patent/KR20200130356A/ko not_active Ceased
- 2019-03-06 SG SG11202007865VA patent/SG11202007865VA/en unknown
- 2019-03-06 WO PCT/US2019/021024 patent/WO2019173523A1/en not_active Ceased
-
2020
- 2020-08-17 IL IL276768A patent/IL276768A/en unknown
-
2024
- 2024-01-12 JP JP2024002970A patent/JP2024045219A/ja active Pending